|
|
|
29.05.26 - 12:12
|
Pfizer and Innovent Biologics sign $10.5bn cancer drug development deal (PBR)
|
|
|
The agreement covers antibody-drug conjugates with new payloads and multi-specific antibodies featuring distinct immune-engaging mechanisms. The portfolio consists of eight drug candidates originating from Innovent Biologics and four
The post Pfizer and Innovent Biologics sign $10.5bn cancer drug development deal appeared first on Pharmaceutical Business review....
|
|
|
|
|
29.05.26 - 07:30
|
China′s Innovent Biologics signs US$10.5 billion Pfizer deal for 12 cancer drug trials (SCMP)
|
|
|
China's Innovent Biologics has signed a global collaboration with pharmaceutical giant Pfizer worth up to US$10.5 billion to jointly develop 12 cancer treatment programmes.
The Hong Kong-listed drug maker said it would receive an upfront payment of US$650 million from Pfizer, and it is eligible for up to US$9.85 billion tied to development, regulatory and commercial milestone payments, according to an exchange filing on Friday.
Innovent, which is based in Suzhou in China's eastern Jiangsu......
|
|
|
29.05.26 - 07:03
|
Dividenden-Aktie Pfizer: Milliarden-Deal in China (Der Aktionaer)
|
|
|
Der US-amerikanische Pharma-Riese Pfizer verstärkt seine Entwicklungspipeline. Für bis zu 10,5 Milliarden Dollar sichert sich das Unternehmen die Rechte an zwölf Wirkstoffen der chinesischen Innovent Biologics. Die Aktie der Asiaten gewinnt an der Heimatbörse nach Bekanntwerden des Deals um rund zehn Prozent....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
